ClinicalTrials.gg
CompletedNCT00696436Updated Apr 19, 2011Results posted

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

A Phase 3 interventional study of Azilsartan medoxomil and Azilsartan medoxomil in Hypertension, sponsored by Takeda. Completed at 131 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-19.

Primary conditionEssential HypertensionRegistry: HypertensionReclassifiedWhy we changed it
Registry
Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Essential Hypertension
Why
  1. The study's title name Essential Hypertension, a narrower term within Hypertension.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,291
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.

Enrollment
Largest of 11
1,291 · median 837
Started
2008
with 1 other
Phase 3
10 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
11 of 11
Takeda

Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one has the largest enrollment, is one of 2 that started in 2008, is one of 10 in phase 3, and was the 1st registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing azilsartan medoxomil in Essential Hypertension as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to placebo, valsartan and olmesartan in participants with essential hypertension.

Read the detailed description

Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive treatments, hypertension remains inadequately controlled: only about one-third of patients successfully maintain control.

A major component of blood pressure regulation is the renin-angiotensin-aldosterone system. This is a system of hormone-mediated feedback interactions that result in the relaxation or constriction of blood vessels in response to various stimuli. Angiotensin II, a polypeptide hormone, is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme as part of the renin-angiotensin-aldosterone system. Angiotensin II is the principal pressor agent of the renin-angiotensin-aldosterone system and has multiple effects on the cardiovascular system and on electrolyte homeostasis.

TAK-491 (azilsartan medoxomil) is an angiotensin II type 1 receptor antagonist currently being tested as a treatment for essential hypertension.

Study participation is anticipated to be about 10 weeks. Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, physical examinations, electrocardiograms and ambulatory blood pressure monitoring. Outside of the study center, participants will be required wear an ambulatory blood pressure monitoring device at 24 hour intervals.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Essential Hypertension
  • Cardiovascular Disease
  • High Blood Pressure
  • Drug Therapy
04

In context

Essential Hypertension Reclassified

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

This study's enrollment of 1,291 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg, inclusive, at Day -1 and 24-hour mean systolic blood pressure between 130 and 170 mm Hg, inclusive, at Day 1).
  2. Capable of understanding and complying with protocol requirements.
  3. Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study
  4. Clinical laboratory evaluations within the reference range for the testing laboratory or the results are deemed not for inclusion into this study by the investigator.
  5. Willing to discontinue current antihypertensive medications at Screening Day 21 visit. If the participant is on amlodipine prior to Screening, the participant is willing to discontinue this medication at Screening Day -28.

Exclusion criteria

Exclusion Criteria:

  1. Sitting diastolic blood pressure greater than 114 mm Hg at Day -1 (day prior to Randomization).
  2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.
  3. Taking or expected to take an excluded medication as described in the Excluded Medications.
  4. Hypersensitive to angiotensin II receptor blockers.
  5. History of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or .
  6. cardiac conduction defects.
  7. Hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
  8. Secondary hypertension of any etiology.
  9. Noncompliant (less than 70% or greater than 130%) with study medication during run-in period.
  10. Moderate to severe renal dysfunction or disease.
  11. Known or suspected unilateral or bilateral renal artery stenosis.
  12. History of drug or alcohol abuse within the past 2 years.
  13. Previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not apply to those participants with basal cell or stage I squamous cell carcinoma of the skin).
  14. Type 1 or poorly-controlled type 2 diabetes mellitus (glycosylate greater than 8.0%) at Screening.
  15. Hyperkalemia as defined by the central laboratory normal reference range at Screening.
  16. level of greater than 2.5 times the , active liver disease, or jaundice at Screening.
  17. Upper arm circumference less than 24 cm or greater than 42 cm.
  18. Works night (3rd) shift (defined as 11 PM [2300] to 7 AM [0700]).
  19. Unwilling or unable to comply with the protocol or scheduled appointments.
  20. Currently is participating in another study or has participated in an investigational study within 30 days prior to Randomization.
  21. Any other serious disease or condition at Screening or Randomization that would compromise participant's safety, might affect , or make it difficult to successfully manage and follow the subject according to the protocol.
  22. Has been randomized in a previous azilsartan medoxomil study.
  23. Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,291 participants (actual)

Study arms

  • Experimental
    Azilsartan Medoxomil 40 mg QD

    Drug: Azilsartan medoxomil

  • Experimental
    Azilsartan Medoxomil 80 mg QD

    Drug: Azilsartan medoxomil

  • Active comparator
    Valsartan 320 mg QD

    Drug: Valsartan

  • Active comparator
    Olmesartan 40 mg QD

    Drug: Olmesartan

  • Placebo comparator
    Placebo QD

    Drug: Placebo

Interventions

  • Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks. Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.

    Also known as: TAK-491, Edarbi

  • Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks. Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.

    Also known as: TAK-491, Edarbi

  • Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks. Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.

    Also known as: Diovan®

  • Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks. Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.

    Also known as: Benicar®

  • DrugPlacebo

    Matching placebo, orally, once daily for up to six weeks.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 6.

Secondary outcomes

  1. Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.

    The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.

    Time frame: Baseline and Week 6.

  2. Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 6.

  3. Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure

    The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.

    Time frame: Baseline and Week 6.

  4. Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 6.

  5. Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 6.

  6. Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 6.

  7. Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 6.

  8. Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 6.

  9. Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 6.

  10. Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 6.

  11. Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 6.

  12. Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg

    Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 6.

  13. Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg

    Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

    Time frame: Baseline and Week 6.

  14. Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response

    Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.

    Time frame: Baseline and Week 6.

08

Results

Posted Apr 19, 2011

Participant flow

Participants enrolled at 141 investigative sites in Guatemala, Mexico, Peru, Puerto Rico and the United States from 02 April 2008 to 19 August 2009.

Participant flow — Overall Study
MilestoneAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Started280285282290154
Completed257255254268141
Not completed2330282213
Withdrew: Adverse event79864
Withdrew: Protocol violation32201
Withdrew: Lost to follow-up16243
Withdrew: Withdrawal by subject411571
Withdrew: Lack of efficacy31524
Withdrew: Participant unavailability20210
Withdrew: Administrative error20200
Withdrew: Participant non-compliance00120
Withdrew: Administrative decision10000
Withdrew: Missing01100

Outcome measures

PrimaryChange From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-13.42 ± 0.690-14.53 ± 0.702-10.22 ± 0.696-11.99 ± 0.666-0.25 ± 0.917
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.) · Mean difference (final values): -14.27 · 95% CI -16.54 to -12.01
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.) · Mean difference (final values): -13.16 · 95% CI -15.41 to -10.91
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.009 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.) · Mean difference (final values): -2.54 · 95% CI -4.44 to -0.64
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.) · Mean difference (final values): -4.31 · 95% CI -6.25 to -2.37
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.136 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.) · Mean difference (final values): -1.43 · 95% CI -3.31 to 0.45
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.) · Mean difference (final values): -3.20 · 95% CI -5.12 to -1.27
SecondaryChange From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.

The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.-16.38 ± 0.959-16.74 ± 0.957-11.31 ± 0.955-13.20 ± 0.935-1.83 ± 1.293
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.) · Mean difference (final values): -14.92 · 95% CI -18.07 to -11.76
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.) · Mean difference (final values): -14.55 · 95% CI -17.71 to -11.40
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.008 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.) · Mean difference (final values): -3.54 · 95% CI -6.17 to -0.92
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.) · Mean difference (final values): -5.43 · 95% CI -8.09 to -2.78
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.018 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.) · Mean difference (final values): -3.18 · 95% CI -5.81 to -0.55
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.) · Mean difference (final values): -5.07 · 95% CI -7.73 to -2.42
SecondaryChange From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-8.65 ± 0.472-9.43 ± 0.480-7.09 ± 0.476-7.74 ± 0.456-0.07 ± 0.627
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -9.36 · 95% CI -10.91 to -7.81
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -8.58 · 95% CI -10.12 to -7.04
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.011 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -1.70 · 95% CI -2.99 to -0.40
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -2.35 · 95% CI -3.67 to -1.02
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.166 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -0.91 · 95% CI -2.19 to 0.38
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.020 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -1.56 · 95% CI -2.88 to -0.24
SecondaryChange From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure

The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure-6.97 ± 0.552-8.27 ± 0.551-5.11 ± 0.550-6.10 ± 0.538-0.76 ± 0.744
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -7.51 · 95% CI -9.33 to -5.69
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -6.21 · 95% CI -8.03 to -4.39
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.005 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -2.18 · 95% CI -3.69 to -0.67
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -3.17 · 95% CI -4.69 to -1.64
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.257 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -0.87 · 95% CI -2.39 to 0.64
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.017 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -1.86 · 95% CI -3.39 to -0.33
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-13.73 ± 0.724-15.02 ± 0.736-10.26 ± 0.730-12.16 ± 0.699-0.11 ± 0.963
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -14.92 · 95% CI -17.30 to -12.54
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -13.63 · 95% CI -15.99 to -11.27
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.005 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -2.86 · 95% CI -4.85 to -0.87
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -4.76 · 95% CI -6.80 to -2.73
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.119 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -1.57 · 95% CI -3.55 to 0.40
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -3.47 · 95% CI -5.49 to -1.45
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-8.96 ± 0.510-9.80 ± 0.518-7.23 ± 0.514-7.82 ± 0.4920.01 ± 0.677
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -9.81 · 95% CI -11.48 to -8.13
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -8.96 · 95% CI -10.63 to -7.30
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.006 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -1.99 · 95% CI -3.39 to -0.58
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -2.57 · 95% CI -4.00 to -1.14
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.107 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -1.14 · 95% CI -2.53 to 0.25
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.017 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -1.73 · 95% CI -3.15 to -0.30
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-12.28 ± 0.778-13.32 ± 0.792-9.66 ± 0.784-11.90 ± 0.752-0.31 ± 1.035
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -13.00 · 95% CI -15.56 to -10.45
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -11.97 · 95% CI -14.51 to -9.43
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.194 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -1.42 · 95% CI -3.56 to 0.72
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -3.65 · 95% CI -5.84 to -1.46
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.720 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -0.39 · 95% CI -2.51 to 1.73
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.018 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -2.62 · 95% CI -4.79 to -0.45
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-7.65 ± 0.540-8.54 ± 0.550-6.26 ± 0.544-7.82 ± 0.5220.10 ± 0.718
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -8.64 · 95% CI -10.42 to -6.87
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -7.75 · 95% CI -9.52 to -5.99
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.341 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -0.72 · 95% CI -2.21 to 0.77
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.003 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -2.28 · 95% CI -3.80 to -0.76
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.821 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): 0.17 · 95% CI -1.30 to 1.64
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.071 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -1.39 · 95% CI -2.89 to 0.12
SecondaryChange From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-14.03 ± 0.764-15.55 ± 0.777-10.44 ± 0.770-12.23 ± 0.738-0.10 ± 1.016
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -15.45 · 95% CI -17.96 to -12.94
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -13.93 · 95% CI -16.42 to -11.43
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.002 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -3.32 · 95% CI -5.42 to -1.22
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -5.11 · 95% CI -7.26 to -2.97
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.091 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -1.80 · 95% CI -3.88 to 0.29
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -3.59 · 95% CI -5.72 to -1.46
SecondaryChange From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-9.16 ± 0.542-10.13 ± 0.551-7.42 ± 0.547-7.82 ± 0.5240.01 ± 0.721
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -10.14 · 95% CI -11.92 to -8.36
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -9.17 · 95% CI -10.94 to -7.40
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.002 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -2.31 · 95% CI -3.81 to -0.82
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -2.71 · 95% CI -4.24 to -1.19
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.076 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -1.34 · 95% CI -2.82 to 0.14
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.024 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -1.74 · 95% CI -3.25 to -0.22
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-12.46 ± 0.860-13.38 ± 0.873-9.14 ± 0.865-11.65 ± 0.829-0.55 ± 1.142
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -12.84 · 95% CI -15.66 to -10.02
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -11.91 · 95% CI -14.72 to -9.11
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.149 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -1.74 · 95% CI -4.10 to 0.62
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -4.24 · 95% CI -6.65 to -1.83
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.494 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -0.82 · 95% CI -3.16 to 1.53
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.007 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -3.32 · 95% CI -5.72 to -0.93
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-8.69 ± 0.648-8.61 ± 0.657-6.22 ± 0.651-8.25 ± 0.624-0.69 ± 0.859
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -7.91 · 95% CI -10.03 to -5.79
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -7.99 · 95% CI -10.10 to -5.88
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.691 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -0.36 · 95% CI -2.14 to 1.42
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.010 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -2.39 · 95% CI -4.20 to -0.57
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · ANCOVA · p = 0.625 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -0.44 · 95% CI -2.20 to 1.32
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.008 (Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.) · Mean difference (final values): -2.46 · 95% CI -4.27 to -0.66
SecondaryPercentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg

Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg
percentage of participantsAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg56.557.848.748.822.3
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 4.98 · 95% CI 3.15 to 7.88
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 4.66 · 95% CI 2.94 to 7.37
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.032 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 1.45 · 95% CI 1.03 to 2.03
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · Regression, Logistic · p = 0.029 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 1.46 · 95% CI 1.04 to 2.06
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.080 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 1.35 · 95% CI 0.96 to 1.89
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · Regression, Logistic · p = 0.071 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 1.37 · 95% CI 0.97 to 1.92
SecondaryPercentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg

Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg
percentage of participantsAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg68.871.163.868.243.9
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 3.29 · 95% CI 2.10 to 5.15
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 2.91 · 95% CI 1.86 to 4.54
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.306 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 1.22 · 95% CI 0.83 to 1.80
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · Regression, Logistic · p = 0.132 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 1.34 · 95% CI 0.92 to 1.97
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.695 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 1.08 · 95% CI 0.74 to 1.58
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · Regression, Logistic · p = 0.381 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 1.19 · 95% CI 0.81 to 1.74
SecondaryPercentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response

Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
percentage of participantsAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response49.152.643.944.518.2
Statistical analysis
  • Azilsartan Medoxomil 80 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 5.18 · 95% CI 3.20 to 8.41
  • Azilsartan Medoxomil 40 mg QD vs Placebo QD · Regression, Logistic · p = <0.001 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 4.43 · 95% CI 2.73 to 7.19
  • Azilsartan Medoxomil 80 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.056 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 1.39 · 95% CI 0.99 to 1.94
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · Regression, Logistic · p = 0.036 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 1.44 · 95% CI 1.02 to 2.02
  • Azilsartan Medoxomil 40 mg QD vs Olmesartan 40 mg QD · Regression, Logistic · p = 0.317 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 1.19 · 95% CI 0.85 to 1.66
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · Regression, Logistic · p = 0.234 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.) · Odds ratio (or): 1.23 · 95% CI 0.87 to 1.73

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azilsartan Medoxomil 40 mg QD—2/280 (0.7%)18/280 (6.4%)
Azilsartan Medoxomil 80 mg QD—3/284 (1.1%)12/284 (4.2%)
Valsartan 320 mg QD—3/277 (1.1%)21/277 (7.6%)
Olmesartan 40 mg QD—4/290 (1.4%)23/290 (7.9%)
Placebo QD—2/155 (1.3%)14/155 (9%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
Abdominal adhesionsGastrointestinal disorders0/2800/2840/2770/2901/155
FallInjury, poisoning and procedural complications0/2800/2841/2770/2901/155
Intentional overdoseInjury, poisoning and procedural complications0/2800/2841/2770/2900/155
Deep vein thrombosisVascular disorders0/2800/2841/2770/2900/155
CholecystitisHepatobiliary disorders1/2800/2840/2770/2900/155
Dysfunctional uterine bleedingReproductive system and breast disorders1/2800/2840/2770/2900/155
CholelithiasisHepatobiliary disorders1/2800/2840/2770/2900/155
Eye irritationEye disorders0/2801/2840/2770/2900/155
Gastrointestinal haemorrhageGastrointestinal disorders0/2801/2840/2770/2900/155
DiverticulitisInfections and infestations0/2801/2840/2770/2900/155
Most frequent other events
Most frequent other events
EventAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QD
HeadacheNervous system disorders18/28012/28421/27723/29014/155

Baseline characteristics

Age Categorical
Age Categorical(participants)Azilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QDTotal
<45 years4138563920194
Between 45 and 64 years17018417818598815
≥65 years6963486636282
Sex: Female, Male
Sex: Female, Male(Participants)Azilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOlmesartan 40 mg QDPlacebo QDTotal
Female13313413013164592
Male14715115215990699
09

Study locations

131 sites
  • Alabaster, Alabama, United States
  • Ozark, Alabama, United States
  • Green Valley, Arizona, United States
  • Litchfield Park, Arizona, United States
  • Mesa, Arizona, United States
  • Tempe, Arizona, United States
  • Carmichael, California, United States
  • Chula Vista, California, United States
  • Lincoln, California, United States
  • Mission Viejo, California, United States
  • National City, California, United States
  • Pasadena, California, United States
  • Riverside, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • San Dimas, California, United States
  • San Fransisco, California, United States
  • San Ramon, California, United States
  • Santa Ana, California, United States
  • Vista, California, United States
  • Colorado Springs, Colorado, United States
  • Denver, Colorado, United States
  • Littleton, Colorado, United States
  • Longmont, Colorado, United States
  • Cape Coral, Florida, United States
  • Clearwater, Florida, United States
  • Largo, Florida, United States
  • Miami, Florida, United States
  • New Port Richey, Florida, United States
  • New Smyrna Beach, Florida, United States
  • Palm Harbor, Florida, United States
  • Tallahassee, Florida, United States
  • Dunwoody, Georgia, United States
  • Roswell, Georgia, United States
  • Arlington Heights, Illinois, United States
  • Belleville, Illinois, United States
  • Champaign, Illinois, United States
  • Chicago, Illinois, United States
  • Peoria, Illinois, United States
  • Vernon Hills, Illinois, United States
  • Evansville, Indiana, United States
  • Indianapolis, Indiana, United States
  • Terre Haute, Indiana, United States
  • Kansas City, Kansas, United States
  • Overland Park, Kansas, United States
  • Shawnee, Kansas, United States
  • Biddeford, Maine, United States
  • Norwood, Maine, United States
  • Baltimore, Maryland, United States
  • Towson, Maryland, United States
  • Brooklyn Center, Minnesota, United States
  • Chesterfield, Missouri, United States
  • Jefferson City, Missouri, United States
  • Kansas City, Missouri, United States
  • St Louis, Missouri, United States
  • Billings, Montana, United States
  • Las Vegas, Nevada, United States
  • Margate, New Jersey, United States
  • Glens Falls, New York, United States
  • Great Neck, New York, United States
  • New Hyde Park, New York, United States
  • New Windsor, New York, United States
  • New York, New York, United States
  • Charlotte, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Columbus, Ohio, United States
  • Norman, Oklahoma, United States
  • Tulsa, Oklahoma, United States
  • Yukon, Oklahoma, United States
  • Ashland, Oregon, United States
  • Eugene, Oregon, United States
  • Medford, Oregon, United States
  • Portland, Oregon, United States
  • Pittsburgh, Pennsylvania, United States
  • Tipton, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Murrells Inlet, South Carolina, United States
  • North Charleston, South Carolina, United States
  • Cleveland, Tennessee, United States
  • Bedford, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Missouri City, Texas, United States
  • San Antonio, Texas, United States
  • Sugarland, Texas, United States
  • Tacoma, Washington, United States
  • Carlos Paz, Córdoba, Argentina
  • Guaymayen, Mendoza, Argentina
  • Bahía Blanca, Argentina
  • Berazategui, Argentina
  • Buenos Aires, Argentina
  • Corrientes, Argentina
  • Córdoba, Argentina
  • Haedo Pcia. de Buenos Aires, Argentina
  • Jujuy, Argentina
  • La Plata, Argentina
  • Ramos Mejía Pcia. de Buenos Aires, Argentina
  • Rosario, Argentina
  • Salta, Argentina
  • San Miguel de Tucumán, Argentina

Showing the first 100 of 131 sites across 6 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar;57(3):413-20. doi: 10.1161/HYPERTENSIONAHA.110.163402. Epub 2011 Jan 31. PubMed 21282560 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2008
First posted
Jun 12, 2008
Start
Apr 2008
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Apr 19, 2011
Last update
Apr 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00696436
Lead sponsor
Takeda
First posted
Jun 12, 2008
Start date
Apr 2008
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Apr 19, 2011
Last update
Apr 19, 2011

Study contacts

Executive Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azilsartan medoxomil

Start the discussion